NCT00207116

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (planned)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Conditions

• Carcinoma, Non-Small-Cell Lung
• Neoplasm Metastasis

Interventions

Type	Name	Description
DRUG	Cetuximab	IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.

Timeline

• Start date: 2005-09-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-09-21
• Last updated: 2015-10-28

Locations

1 site across 1 country: United States